Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options
BRAF mutations occur in up to 50% of melanomas. Mutations in the BRAF gene directly influence the patient’s treatment because several inhibitors are available that only target BRAFV600 mutations. Herein, we describe two cases of patients with metastatic melanomas, each carrying a ‘nonstandard’ mutat...
Main Authors: | Georg Richtig, Ariane Aigelsreiter, Karl Kashofer, Emina Talakic, Romana Kupsa, Helmut Schaider, Erika Richtig |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2016-09-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/449125 |
Similar Items
-
Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
by: Fedor V. Moiseyenko, et al.
Published: (2019-05-01) -
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
by: Gabriele Madonna, et al.
Published: (2021-08-01) -
BRAF and beyond: Tailoring strategies for the individual melanoma patient
by: Anthony Jarkowski, et al.
Published: (2014-01-01) -
Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
by: Takayo Ota, et al.
Published: (2021-10-01) -
Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
by: Po-Lan Su, MD, et al.
Published: (2021-08-01)